Taking everything into account, COCP scores 2 out of 10 in our fundamental rating. COCP was compared to 191 industry peers in the Pharmaceuticals industry. While COCP has a great health rating, there are worries on its profitability. COCP is valued expensive and it does not seem to be growing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -92.58% | ||
| ROE | -126.11% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -44.93 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.78 | ||
| Quick Ratio | 5.78 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
0.9608
-0.02 (-1.96%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.73 | ||
| P/tB | 1.73 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -92.58% | ||
| ROE | -126.11% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 11.76% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.78 | ||
| Quick Ratio | 5.78 | ||
| Altman-Z | -44.93 |
ChartMill assigns a fundamental rating of 2 / 10 to COCP.
ChartMill assigns a valuation rating of 0 / 10 to COCRYSTAL PHARMA INC (COCP). This can be considered as Overvalued.
COCRYSTAL PHARMA INC (COCP) has a profitability rating of 0 / 10.
The Earnings per Share (EPS) of COCRYSTAL PHARMA INC (COCP) is expected to grow by 53.13% in the next year.